A Phase I/II Study to Assess the Effect of Soluble Beta-1,3/1,6-glucan in Combination With Standard Therapy in Patients With Breast Cancer

NCT00533364 Phase 1/Phase 2 COMPLETED

This study is set up to determine whether soluble beta-glucan (SBG) has * unfavourable side effects * beneficial treatment effects when given in combination with standard antibody and chemotherapy to patients with breast cancer.

Details

Lead sponsor	Biotec Pharmacon ASA
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	11
Start date	2007-01
Completion	2010-01

Conditions

• Breast Cancer

Interventions

• SBG (Soluble beta-glucan)

Primary outcomes

• Asess the safety of SBG in combination with standard antibody and chemotherapy treatment — 21 weeks

Countries

Norway